Evaluation of nucleic acid testing for blood donors: One year study

Alturaifi, Hussain

doi:10.5348/ijbti-2015-18-oa-4

Cited by 3 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus lowering NAT cost is a necessity to implement such a plan on the national level (34). Similarly, Al-Turaifi (35) found that the effectiveness of NAT for blood donors screening is an area of debate that a widenational study is essential to weigh the safety and costeffectiveness of implementing conventional and NAT assays for screening of blood donations.…”

Section: Discussionmentioning

confidence: 99%

Optimization of Pooling Technique for Hepatitis C Virus Nucleic Acid Testing (NAT) in Blood Banks

et al. 2020

View full text Add to dashboard Cite

Background: Blood safety is an important health issue, especially in Egypt with a high prevalence of HCV infection and recent massive efforts for control. Objectives: The study was conducted to evaluate the feasibility of the nucleic acid amplification technique (NAT) in Egyptian blood banks. Methods: A total of 12,036 plasma sample donations collected from two Egyptian blood banks were screened by NAT using a chessboard pooling scheme. The donations were divided into two groups: Group 1 included 10,020 seronegative, while Group 2 included 2,016 blindly tested donations. Results: Out of the total donations, seven tests were positive by NAT. The serology results of those seven seronegative donations were confirmed. They were also retested individually by NAT. The pool format 6x12 was the most reliable for screening. The cost of NAT was reduced to one-quarter and the positive sample in the pool was easily pointed by using the chessboard format. Conclusions: The study demonstrated the importance of introducing NAT for HCV screening in Egyptian blood banks by adopting a pooling scheme to reduce cost.

show abstract

Section: Discussionmentioning

confidence: 99%

Optimization of Pooling Technique for Hepatitis C Virus Nucleic Acid Testing (NAT) in Blood Banks

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The window period for detection by ID-NAT by ultrio plus is 4.7 days for HIV-1, 2.2 days for HCV and 16.3 days for HBV. 11,12 The corresponding window periods for serological test are 15-20 days, 2-26 weeks and 50-150 days respectively. 13 Voluntary to replacement donors ratio in our study is 85.08% : 14.98% which can be compared to the study done by Jain et al 16 in which the ratio was 84.65% : 15.35%, however in few other studies replacement donors were more than voluntary donors 35.2%:64.8%, 13 3,225:8999 14 and 99.3%:0.7% 11 .…”

Section: Discussionmentioning

confidence: 99%

Evaluation of nucleic acid testing [NAT] of blood donors

Chaithanya¹,

Shivakumar²

2020

IJPO

View full text Add to dashboard Cite

Context: Human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) are easily transmitted through infected blood, to prevent this serological screening of blood units is a routine norm. Many cases could be missed if the testing is done in window period. To overcome this and to provide an additional protection many tests with better sensitivity and specificity like Nucleic acid testing (NAT) have been tried. Aims: To observe NAT reactivity trend for transfusion transmittable diseases, and to correlate ELISA and NAT methods in detecting HIV, HBV and HCV. Materials and Methods: A six years retrospective observational study conducted in Blood bank, Department of Pathology. ELISA and ID-NAT results of the donor samples for HIV, HBV and HCV were collected in a specially designed proforma and analyzed. Statistical Analysis used: Data entered in Microsoft excel sheets, means and percentages were calculated. Results: In 6years 52,417 units of blood collected, 44,600(85.08%) were voluntary donors and 7,817(14.92%) replacement donors. There were 521(0.99%) cases of HBV, 98 (0.19%) HIV and 48 (0.09%) HCV and two cases of HIV-HBV co-infection. About 557 were positive by both ELISA and NAT method (1.06%). Fifty eight cases were positive only by ID-NAT method and negative on serological testing accounting to the NAT yield of 1 in 893 cases. There were 2 cases of HIV-2 which were missed by NAT and picked up in ELISA. Conclusions: Screening of blood and blood products using dual testing with high sensitivity serological assays and NAT helps to detect potentially infectious diseases in all phases of infection.

show abstract